Q-omics provides the consensus-scored RPL21P34 profile across patient tissues and cancer cell-line models. RPL21P34 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL21P34 is differentially expressed in 6, with the highest sampling consensus in LIHC. Additionally, RPL21P34 RNA expression shows 6,817 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, LIHC, and TGCT as cancer lineages where RPL21P34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL21P34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL21P34 survival associations across molecular data types. RPL21P34 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL21P34 RNA expression–survival associations across cancer types. High RPL21P34 expression shows unfavorable associations in ACC and OV, but favorable associations in SKCM, LAML, THYM and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL21P34 RNA expression.
This table summarizes RPL21P34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL21P34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL21P34 shows lower tumor expression in KICH and KIRP and higher tumor expression in LIHC, BLCA, LUAD and STAD. The LIHC box plot shows higher RPL21P34 RNA expression in tumor versus normal tissue (log2 FC = +0.067, t-test p = .007).
This table shows molecular features associated with RPL21P34 in patient tissues and cancer cell lines. In patient samples, RPL21P34 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
